Dr. Xingli Wang

Obviously, the leading ones is the Keytruda or the old drug, but the Keytruda is probably leading the whole pack.

it covers all different indications and probably up to 40.

Now when we started our PD-1 obviously we're looking into it of what's put our PD-1 different from others.

I think what the winning of the current

PD-1 we have is the clinical development strategy.

When was originally developed, you know, this monoclonal antibody, obviously when you do monoclonal drugs, you also wear, even though we all anti the same molecule, but we are different.

Every monoclonal antibodies, if you develop are different, unless you're doing biosimilars, you know, it's a protein, you have multiple epitopes, each of the epitopes

have different functions maybe in general.

I mean, some of them even non-functional.

And this one, I would not say by choice.

When we designed the sapirulimab, it was just developed one of the monoclonal antibodies.

But we looked into all the indications.

We were seeing small cell lung cancer wasn't successful by the Keytruda.

and also others.

So we started to look into this type of different indications.

So by looking into the preclinical data, by looking into the phase one, we kind of felt this would be the one we can bet on.

And obviously, you know, when you do the drug development, sometimes the luck comes with it.

Biology is not solid science often.

It's a human, you know, it's a living organ, living cells sometimes, depending on the right moment.

and the right mixture, and particularly when we do the clinical trials.